Provided by Tiger Trade Technology Pte. Ltd.

Pacific Biosciences of California

1.82
+0.10506.12%
Post-market: 1.830.0091+0.50%19:56 EST
Volume:7.14M
Turnover:12.83M
Market Cap:549.47M
PE:-1.07
High:1.86
Open:1.80
Low:1.69
Close:1.72
52wk High:2.73
52wk Low:0.8511
Shares:301.91M
Float Shares:298.17M
Volume Ratio:0.84
T/O Rate:2.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7058
EPS(LYR):-1.1288
ROE:-205.90%
ROA:-32.23%
PB:15.23
PE(LYR):-1.61

Loading ...

Pacific Biosciences Shifts Key Executive Responsibilities in Leadership Reshuffle

Reuters
·
Feb 04

Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina

MT Newswires Live
·
Feb 02

Pacific Biosciences of California Inc - Received $48.1 Mln in Net Cash Proceeds

THOMSON REUTERS
·
Feb 02

Pacbio Completes Sale of Short-Read Sequencing Assets

THOMSON REUTERS
·
Feb 02

Press Release: PacBio Completes Sale of Short-Read Sequencing Assets

Dow Jones
·
Feb 02

Pacific Biosciences of California Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 28

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

GlobeNewswire
·
Jan 28

PacBio to Collaborate With n-Lorem Foundation and EspeRare on Precision Therapies for Rare Diseases

Reuters
·
Jan 12

PacBio Reports Preliminary 2025 Revenue of $160 Million with 4% Year-Over-Year Growth

Reuters
·
Jan 12

PacBio HiFi Sequencing Adopted as First-Line Tool for SUDC Research

Reuters
·
Jan 12

Pacific Biosciences of California Inc - Announces Prelim Q4 2025 Revenue of $44.6 Mln

THOMSON REUTERS
·
Jan 12

Pacbio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

THOMSON REUTERS
·
Jan 12

PacBio Unveils CiFi Method for Chromosome-Scale Genome Assemblies in Single Sequencing Run

Reuters
·
Jan 08

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

Pacific Biosciences Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Dec 16, 2025

Pacific Biosciences Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Nov 12, 2025

Pacific Biosciences Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
Nov 10, 2025

How China’s Landmark Genomics Approval Has Changed Pacific Biosciences’ (PACB) Investment Story

Simply Wall St.
·
Nov 07, 2025

Stock Track | Pacific Biosciences Plummets 11.75% Pre-Market Following Mixed Q3 Results and Cash Concerns

Stock Track
·
Nov 06, 2025

Stock Track | Pacific Biosciences Plunges 8.62% After Hours on Mixed Q3 Results and Revenue Decline

Stock Track
·
Nov 06, 2025